**S7 Table. Inclusion criteria for courses of treatment eligible for nadir analysis.**

|  |
| --- |
| * ctDNA detectable at baseline (≥20 amplifications/ml)
 |
| * Consecutive samples with at least 1 sample per cycle available to a nadir point or ctDNA falls to 0
 |
| * For patients who completed a line of treatment (either as the course is complete or due to cancer progression) in whom ctDNA is still falling, the last (lowest) reading is taken as the nadir
 |
| * ctDNA is evaluable up to and including 1 cycle length from day 1 of their final cycle
 |
| * Patients with ascitic drains that could potentially interfere with nadir analysis were excluded or who had recent radiotherapy that could interfere.
 |